Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 03, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm to Participate in Upcoming Investor Conferences
August 28, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that the Company’s management team will...
Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
August 21, 2019 17:20 ET
|
Karyopharm Therapeutics Inc.
-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38...
Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
August 06, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
− XPOVIO™ Commercial Launch Underway Following July 3rd FDA Accelerated Approval − − XPOVIO is the First and Only Prescription Medicine Approved in the U.S. for the Treatment of Patients with...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 01, 2019 16:05 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019
July 30, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019...
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
July 03, 2019 13:06 ET
|
Karyopharm Therapeutics Inc.
-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 28, 2019 16:37 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
June 19, 2019 11:05 ET
|
Karyopharm Therapeutics Inc.
-- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate, Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response...
Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
June 14, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral...